comscoreSABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

Dr. Rashmi Murthy discusses the results of the HER2CLIMB study and the benefits of tucatinib.
Apr 22, 2020
00:00
Download
00:00

Dr. Murthy discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.

Listen to the episode to hear Dr. Murthy explain:

  • a summary of the study results

  • why this study included people with brain metastases

  • the side effects of tucatinib

  • why she thinks the results are practice changing

About the guest
 
Rashmi Murthy, MD

Dr. Rashmi Murthy is assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston.

— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate